Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: Metadata referenced Merck & Co., Inc., but the filing text is for Schering-Plough).
Reporting Period: Quarterly period ended March 31, 2004 (Form 10-Q).
Overview: Schering-Plough is a research-based pharmaceutical company facing significant financial strain due to a confluence of negative events over the past three years. Key challenges include the loss of marketing exclusivity for its leading product, CLARITIN (switched to OTC), intense competition in the hepatitis C franchise (INTRON/REBETOL), and substantial costs associated with an FDA consent decree regarding manufacturing practices. The company reported a net loss for the quarter, contrasting with a profit in the prior year.
Key Financial Metrics
| Metric ($ millions) | Q1 2004 | Q1 2003 |
|---|---|---|
| Net Sales | $1,963 | $2,082 |
| Cost of Sales | $740 | $658 |
| Gross Profit | $1,223 | $1,424 |
| Operating Expenses (SG&A + R&D) | $1,286 | $1,165 |
| Special Charges | $70 | $0 |
| Equity Income (Cholesterol JV) | ($78) | $30 |
| Income Before Taxes | ($91) | $216 |
| Net (Loss)/Income | ($73) | $173 |
| Diluted EPS | ($0.05) | $0.12 |
| Cash from Operations | $229 | $441 |
| Cash & Equivalents (End of Period) | $3,932 | $3,340 |
| Total Debt (Short + Long Term) | $3,213 | $3,433 |
Note: Equity income from the cholesterol joint venture is presented as a negative expense (income) in the table above to reflect its contribution to income, consistent with the statement of operations where it reduced the loss.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6% ($119 million) year-over-year. This was driven by an 11% volume decline, partially offset by a 6% favorable foreign exchange impact. U.S. sales dropped 23%, while international sales rose 10%.
- Profitability Reversal: The company swung from a net income of $173 million in Q1 2003 to a net loss of $73 million in Q1 2004. This was primarily due to lower sales, higher operating costs, and $70 million in special charges.
- Special Charges: Q1 2004 included $70 million in special charges: $44 million for employee termination costs (severance and retirement benefits) and $26 million for asset impairment (exit from a European R&D facility).
- Product Performance:
- Declines: PEG-INTRON sales fell 33% due to competition; REBETOL sales fell 55% due to generic entry; CLARINEX sales fell 25% due to market contraction.
- Growth: REMICADE sales increased 45%; NASONEX sales increased 78%; TEMODAR sales increased 46%.
- Cash Flow: Operating cash flow decreased 48% to $229 million. This decline was mitigated by a $404 million U.S. tax refund related to loss carrybacks.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management states that the current business model is not sustainable without a dramatic change in the financial situation. The company intends to seek access to capital markets in 2004 to obtain additional financing for general corporate purposes, including refinancing debt and funding litigation costs. The company's ability to generate profits is heavily dependent on the U.S. approval and commercial success of VYTORIN (ezetimibe/simvastatin), a joint venture product with Merck. If VYTORIN does not provide material cash flow, the company may evaluate strategic alternatives.
Key Risks and Contingencies
- Regulatory and Legal Investigations: The company is under investigation by U.S. Attorneys' Offices in Pennsylvania and Massachusetts regarding sales and marketing practices (including off-label promotion and Medicaid rebate calculations). Litigation reserves were increased by $350 million in Q3 2003. The company is also a target of a federal criminal investigation ("Boston Target Letter").
- FDA Consent Decree: A 2002 consent decree regarding Good Manufacturing Practices (cGMP) requires revalidation of manufacturing processes by late 2005. Failure to meet deadlines could result in fines up to $175 million and potential production halts. The decree cannot be lifted before May 2007.
- Credit Ratings: Credit ratings have been downgraded by S&P (to A-), Moody's (to A3), and Fitch (to A-). Further downgrades could increase borrowing costs and restrict access to commercial paper markets.
- Interest Rate Swaps: Due to credit rating downgrades, an early termination event has occurred for certain interest rate swap arrangements. The company is negotiating termination, which involved a $400 million cash payment to foreign affiliates in April 2004.
- Patent Expirations: Generic versions of REBETOL entered the U.S. market in April 2004, significantly impacting the hepatitis C franchise.
Investor Verification Checklist
- VYTORIN Approval Status: Verify the timeline and likelihood of U.S. FDA approval for VYTORIN, as this is the primary driver for future cash flow recovery.
- Litigation Reserves: Monitor updates on the Massachusetts and Pennsylvania investigations to assess if the $350 million reserve is sufficient or if additional provisions are needed.
- Capital Markets Access: Confirm the effectiveness of the $2 billion shelf registration filed in March 2004 and the company's ability to issue debt/equity given current credit ratings.
- FDA Decree Compliance: Track progress on the cGMP revalidation program to ensure no additional fines or production stoppages occur.
- Foreign Cash Repatriation: Assess the company's strategy for accessing foreign cash reserves (approx. 90% of total cash) and the associated U.S. tax implications, given the current U.S. operating losses.